{"id":"https://openalex.org/W4403568802","doi":"https://doi.org/10.1016/j.htct.2024.09.832","title":"PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOID LEUKEMIA WITH BCR::ABL1 FUSION","display_name":"PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOID LEUKEMIA WITH BCR::ABL1 FUSION","publication_year":2024,"publication_date":"2024-10-01","ids":{"openalex":"https://openalex.org/W4403568802","doi":"https://doi.org/10.1016/j.htct.2024.09.832"},"language":"en","primary_location":{"id":"doi:10.1016/j.htct.2024.09.832","doi":"https://doi.org/10.1016/j.htct.2024.09.832","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2024.09.832","pdf_url":null,"source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.1016/j.htct.2024.09.832","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"MCS Sousa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"MCS Sousa","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086027643","display_name":"Luize Otero","orcid":"https://orcid.org/0000-0002-3455-7603","observed_orcids":["https://orcid.org/0000-0002-3455-7603"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"L Otero","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":null,"display_name":"AF Monteiro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"AF Monteiro","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073596260","display_name":"NC Amaral","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"NC Amaral","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075418090","display_name":"M Magalh\u00e3es Rocha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"MM Rocha","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":null,"display_name":"ILS Pinto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"ILS Pinto","raw_affiliation_strings":["Departamento de Hematologia, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Hematologia, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087470386","display_name":"Ilana Renault Zalcberg","orcid":"https://orcid.org/0000-0002-0229-0430","observed_orcids":["https://orcid.org/0000-0002-0229-0430"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"I Zalcberg","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038680553","display_name":"BCR Monte-M\u00f3r","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"BCR Monte-M\u00f3r","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004066980","display_name":"Luciana M. Gutiyama","orcid":"https://orcid.org/0000-0002-1644-8120","observed_orcids":["https://orcid.org/0000-0002-1644-8120"]},"institutions":[{"id":"https://openalex.org/I4210142683","display_name":"Instituto Nacional de C\u00e2ncer - INCA","ror":"https://ror.org/055n68305","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210142683"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"LM Gutiyama","raw_affiliation_strings":["Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Divis\u00e3o de Laborat\u00f3rios Especializados, Instituto Nacional de C\u00e2ncer (INCA), Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I4210142683"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210142683"],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.2978,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.59895003,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"46","issue":null,"first_page":"S495","last_page":"S495"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcr-abl-fusion","display_name":"BCR-ABL fusion gene","score":0.8870000243186951},{"id":"https://openalex.org/keywords/accelerated-phase-cml","display_name":"accelerated phase CML","score":0.628000020980835},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.7129999995231628},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.8980000019073486},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7419999837875366},{"id":"https://openalex.org/keywords/molecular-monitoring","display_name":"molecular monitoring","score":0.453000009059906},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.49300000071525574},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.5720000267028809},{"id":"https://openalex.org/keywords/eosinophilia","display_name":"eosinophilia","score":0.6159999966621399},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.734000027179718},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8438395261764526},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.8363045454025269},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.7591896057128906},{"id":"https://openalex.org/C43907098","wikidata":"https://www.wikidata.org/wiki/Q903924","display_name":"breakpoint cluster region","level":3,"score":0.5425915718078613},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46096038818359375},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.26010066270828247},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.2195506989955902},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20672008395195007},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08753660321235657},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.05982944369316101},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.036849528551101685}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.htct.2024.09.832","doi":"https://doi.org/10.1016/j.htct.2024.09.832","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2024.09.832","pdf_url":null,"source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:93de97c69fd04daa85c2b2caf971a15b","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/93de97c69fd04daa85c2b2caf971a15b","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S495- (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.htct.2024.09.832","doi":"https://doi.org/10.1016/j.htct.2024.09.832","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2024.09.832","pdf_url":null,"source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005692885","https://openalex.org/W2129033535","https://openalex.org/W1582301735","https://openalex.org/W2315515594","https://openalex.org/W2058478473","https://openalex.org/W2422095050","https://openalex.org/W2164887050","https://openalex.org/W1603236395","https://openalex.org/W2407074269","https://openalex.org/W2048012015"],"abstract_inverted_index":{"Chronic":[0],"myeloid":[1,109,236],"leukemia":[2],"(CML)":[3],"is":[4,38],"a":[5,52,56,206,251,273,341,347,402,411,456],"myeloproliferative":[6],"neoplasm":[7],"characterized":[8,230],"by":[9,121,149,157,231,286,294,390,431,467],"the":[10,23,28,69,104,114,137,179,198,221,283,289,295,309,319,322,387,395,399,422,436],"chromosome":[11,20,416,426],"philadelphia":[12],"(Ph)":[13],"in":[14,78,111,169,175,208,243,277,304],"90-95%":[15],"of":[16,55,72,108,117,182,344,401,438],"cases.":[17],"The":[18,33,64,128,302],"Ph":[19],"results":[21],"from":[22,247,368,415],"reciprocal":[24],"t(9;22)(q34.1;q11.2)":[25],"and":[26,46,87,98,113,141,189,214,233,249,272,381,408,442,469],"encodes":[27],"fusion":[29,184,275],"gene":[30,165],"BCR::ABL1":[31,118,183,260,284,296,353],".":[32],"chimeric":[34],"tyrosine":[35],"kinase":[36],"oncoprotein":[37],"constitutively":[39],"activated,":[40],"leading":[41],"to":[42,68,136,167,197,202,205,210,308,357,394],"continuous":[43],"cell":[44,314],"proliferation":[45],"driving":[47],"leukemogenesis.":[48],"Herein,":[49],"we":[50],"present":[51],"rare":[53,342],"case":[54,339],"36-years-old":[57],"male":[58],"patient":[59,65,105,129,222,320],"diagnosed":[60],"with":[61,145,225,282,334,346,446,455],"Ph-negative":[62,359],"CML.":[63,360],"was":[66,119,130,147,155,223,241,292,332],"admitted":[67],"Hematology":[70],"Department":[71],"Instituto":[73],"Nacional":[74],"de":[75],"C\u00e2ncer":[76],"(INCA)":[77],"September":[79],"2019":[80],"presenting":[81],"persistent":[82],"fever,":[83],"splenomegaly,":[84],"weight":[85],"loss":[86],"night":[88],"sweats.":[89],"Blood":[90],"workup":[91],"showed":[92],"significant":[93],"leukocytosis":[94],"(229.450/\u03bcL),":[95],"thrombocytosis":[96],"(639.000/\u03bcL)":[97],"eosinophilia":[99],"(16.000/\u03bcL,":[100],"7%).":[101],"At":[102],"diagnosis,":[103,452],"exhibited":[106],"5%":[107],"blasts":[110],"blood":[112],"b2a2":[115],"isoform":[116],"detected":[120,293],"qualitative":[122,158],"reverse-transcription":[123],"polymerase":[124],"chain":[125],"reaction":[126],"(RT-PCR).":[127],"classified":[131],"as":[132,358,453],"high":[133],"risk":[134],"according":[135],"Sokal":[138],"Index":[139],"(2.1)":[140],"his":[142],"initial":[143],"treatment":[144,203,329],"hydroxyurea":[146],"followed":[148],"Imatinib":[150],"(600":[151],"mg/day).":[152],"Molecular":[153],"monitoring":[154],"performed":[156,242],"RT-PCR":[159,172],"for":[160,311,352,449],"p210,":[161],"because":[162],"ABL":[163,270],"control":[164],"failed":[166],"amplify":[168],"our":[170],"quantitative":[171],"(qPCR)":[173],"assay":[174],"several":[176],"samples,":[177],"despite":[178],"successful":[180],"amplification":[181],"gene.":[185],"After":[186],"18":[187],"months,":[188,193],"again":[190],"after":[191],"42":[192],"clinical":[194,336],"worsening":[195],"due":[196],"patient's":[199],"low":[200],"adherence":[201],"led":[204,307],"change":[207],"therapy":[209],"Nilotinib":[211,328],"(800":[212,330],"mg/dia)":[213,331],"Dasatinib":[215],"(100":[216],"mg/dia),":[217],"respectively.":[218],"In":[219,384],"2023,":[220],"hospitalized":[224],"accelerated":[226],"phase":[227],"CML":[228,345,451],"(AP-CML)":[229],"basophilia":[232],"no":[234],"detectable":[235,466],"blast.":[237],"Conventional":[238],"cytogenetic":[239],"analysis":[240],"bone":[244],"marrow":[245],"sample":[246],"relapse":[248],"revealed":[250],"normal":[252,348,388,457],"karyotype":[253,349,389,458],"(46,":[254],"XY[20]),":[255],"however,":[256],"FISH":[257,396,468],"using":[258],"LSI":[259],"Dual":[261],"Color/Dual":[262],"Fusion":[263],"Probe":[264],"identified":[265],"one":[266],"BCR":[267,423],"signal;":[268],"two":[269],"signals":[271],"single":[274],"signal":[276],"86/100":[278],"nuclei":[279],"analyzed,":[280],"consistent":[281],"detection":[285,430],"RT-PCR.":[287],"Additionally,":[288],"F317L":[290],"mutation":[291,303],"mutational":[297],"testing":[298],"realized":[299],"at":[300],"relapse.":[301],"AP-CML":[305],"scenario":[306],"recommendation":[310],"hematopoietic":[312],"stem":[313],"transplantation.":[315],"Three":[316],"months":[317],"post-transplantation,":[318],"rejected":[321],"graft,":[323],"showing":[324],"complete":[325],"autologous":[326],"recovery.":[327],"reintroduced":[333],"satisfactory":[335],"response.":[337],"This":[338,434],"describes":[340],"instance":[343],"but":[350],"positive":[351],",":[354],"often":[355],"referred":[356],"Literature":[361],"suggests":[362],"that":[363],"those":[364],"cases":[365,454],"may":[366,418,459],"arise":[367],"complex":[369,462],"chromosomal":[370,463],"abnormalities,":[371],"including":[372],"three-way":[373],"or":[374],"multi-way":[375],"translocations":[376],"involving":[377],"chromosomes":[378,406],"9,":[379],"22,":[380,409,427],"additional":[382],"chromosomes.":[383],"this":[385],"case,":[386],"conventional":[391,432,447],"cytogenetics":[392,441,448],"together":[393],"pattern":[397],"implies":[398],"possibility":[400],"cryptic":[403],"insertion":[404],"between":[405],"9":[407,417],"where":[410],"partial":[412],"ABL1":[413],"segment":[414],"have":[419],"inserted":[420],"into":[421],"locus":[424],"on":[425],"thus":[428],"hindering":[429],"cytogenetics.":[433],"highlights":[435],"importance":[437],"integrating":[439],"molecular":[440,443],"biology":[444],"techniques":[445],"comprehensive":[450],"still":[460],"harbor":[461],"abnormalities":[464],"only":[465],"PCR":[470],"testing.":[471]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-10-20T00:00:00"}